Table 3.
Baseline genitourinary symptoms and acute and late genitourinary symptoms and treatment related late toxicity.
| Baseline | Acute symptoms |
Acute toxicity |
Late symptoms |
Late toxicity |
Last late# symptoms |
Last late# toxicity |
||
|---|---|---|---|---|---|---|---|---|
| Toxicity | Grade | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Dysuria | 0 | 264 (99) | 167 (62) | 170 (63) | 247 (92) | 248 (93) | 268 (100) | 268 (100) |
| 1 | 4 (1) | 101 (38) | 98 (37) | 21 (8) | 20 (7) | 0 | 0 | |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Incontinence | 0 | 264 (99) | 262 (98) | 266 (99) | 212 (79) | 214 (80) | 245 (91) | 244 (91) |
| 1 | 4 (1) | 5 (2) | 1 (<1) | 49 (18) | 47 (17) | 19 (7) | 20 (8) | |
| 2 | 0 | 1 (<1) | 1 (<1) | 7 (3) | 7 (3) | 4 (2) | 4 (1) | |
| Retention | 0 | 102 (38) | 67 (25) | 188 (70) | 67 (25) | 186 (69) | 152 (57) | 228 (85) |
| 1 | 101 (38) | 68 (25) | 9 (4) | 101 (38) | 39 (15) | 59 (22) | 18 (7) | |
| 2 | 65 (24) | 133 (50) | 71 (26) | 98 (36) | 41 (15) | 56 (21) | 21(8) | |
| 3 | 0 | 0 | 0 | 2 (1) | 2 (1) | 1 (<1) | 1 (<1) | |
| Frequency/urgency | 0 | 80 (30) | 21 (8) | 202 (75) | 37 (14) | 198 (74) | 136 (51) | 234 (87) |
| 1 | 187 (70) | 242 (90) | 61 (23) | 209 (78) | 48 (18) | 124 (46) | 26 (10) | |
| 2 | 1 (<1) | 5 (2) | 5 (2) | 22 (8) | 22 (8) | 8 (3) | 8 (3) | |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Hematuria | 0 | 263 (98) | 263 (98) | 267 (100) | 230 (86) | 234 (87) | 257 (96) | 258 (96) |
| 1 | 5 (2) | 5 (2) | 1 (<1) | 38 (14) | 34 (13) | 11 (4) | 10 (4) | |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Highest GU* | 0 | 52 (19) | 14 (5) | 86 (32) | 23 (9) | 104 (39) | 102 (38) | 189 (71) |
| 1 | 150 (56) | 122 (46) | 108 (40) | 140 (52) | 107 (40) | 103 (38) | 50 (19) | |
| 2 | 66 (25) | 132 (49) | 74 (28) | 102 (38) | 55 (20) | 62 (23) | 28 (10) | |
| 3 | 0 | 0 | 0 | 2 (1) | 2 (1) | 1 (<1) | 1 (<1) | |
| GU medication used: | n (%) | n (%) | n (%) | n (%) | ||||
| Alpha blockers | 61 (23) | 132 (49) | 114 (42) | 56 (21) | ||||
| 5 Alpha reductase inhibitors | 13 (5) | 6 (2) | 10 (4) | 5 (2) | ||||
| Anticholinergics | 1 (<1) | 6 (2) | 23 (9) | 8 (3) | ||||
| NSAR | 0 | 60 (22) | 3 (1) | 1 (<1) | ||||
Abbreviations: GU=genitourinary; NSAR=non steroid anti-inflammatory drugs;
*
The highest toxicity in a patient was counted as a single event;
#
Incidence of late symptoms or late toxicity at last follow-up visit. There was no grade ≥ grade 4 GU toxicity observed.